Condition: Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma · Sponsor: Tyligand Bioscience (Shanghai) Limited
The study is a first-in-human \[FIH\], open-label phase 1/2 study of TSN222 in subjects with advanced solid tumors or lymphomas. This study is comprised of a Phase 1 dose escalation and Phase 2 dose expansion component.
This description comes directly from the study's public registry record.
Tyligand Clinical Trial Info · 8621-50720081 · clinical_trial@tyligand.com
Always discuss trial participation with your own doctor first.
| Fudan Cancer Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05842785